Purpose of the CAHlibrate Study


The CAHlibrate Study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of an investigational medication in adults with congenital adrenal hyperplasia, or CAH.

The CAHlibrate Study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of an investigational medication in adults with congenital adrenal hyperplasia, or CAH.

WHO MAY QUALIFY.

Eligible participants must meet the following criteria, in addition to other criteria:

  • Male or female between the ages of 18 and 50, inclusive
  • Diagnosed with congenital adrenal hyperplasia
  • Willing and able to comply with the study instructions

There are additional eligibility requirements that the study doctor can explain to you.

STUDY PARTICIPATION.

Participation in the CAHlibrate Study lasts approximately 11 weeks and consists of four periods:

Screening

approximately three weeks

Baseline

24 hours (takes place approximately seven days prior to the first day of dosing)

Dosing

14 days

Follow-up

approximately five weeks

Throughout the study, your study doctor may perform a number of tests and procedures, including but not limited to:

  • Recording your medical history
  • Conducting a physical exam
  • Measuring your vital signs
  • Conducting a pregnancy test (if applicable)
  • Collecting blood and urine samples